The treatment of neuroendocrine tumors is one thing that people are particularly concerned about. Prof. Jie Chen: The treatment methods of neuroendocrine tumors include endoscopic surgery and surgical treatment, radiation interventional therapy, radionuclide therapy, chemotherapy, biological therapy, molecular targeted therapy and so on. How to choose the various treatment methods? Prof. Jie Chen: The choice of treatment depends on the tumor’s classification, stage, site of occurrence and whether it has the function of hormone secretion. The first thing to consider is whether it can be treated surgically. For patients with limited tumors, they can be removed by radical surgery; for patients with progressive tumors, some of them can be palliatively treated by surgical tumor reduction surgery; for patients with liver metastases only, local treatments such as ablation and vascular embolization can be chosen for liver metastases. Then, different drugs are selected according to the tumor site, functional status, pathological grade and tumor stage. The goal of drug therapy is to control the symptoms associated with hormonal overproduction in functional neuroendocrine tumors and to control the growth of the tumor. Pharmacotherapy includes chemotherapy, biologic therapy, and molecular targeted therapy. Specifically, traditional cytotoxic chemotherapy drugs (drugs that kill tumor cells while having certain toxic side effects on normal cells in the body) are still the first-line treatment for poorly differentiated G3 neuroendocrine cancers, while biologic therapy and targeted therapy are the main drug treatments for G1 and G2 neuroendocrine tumors. The main drugs currently used for biologic treatment of neuroendocrine tumors are growth inhibitor analogs, including octreotide and lanreotide; targeted drugs include the mammalian rapamycin target protein inhibitor everolimus and the receptor tyrosine kinase inhibitor sunitinib. What is the prognosis of neuroendocrine tumors? Prof. Jie Chen: The factors affecting the prognosis of neuroendocrine tumors include tumor size, site of development, grading and stage. The survival time of poorly differentiated G3 neuroendocrine cancer is about 10 months. Well-differentiated G1 and G2 neuroendocrine tumors usually progress more slowly, and the survival period ranges from 3 to 20 years. What should be done for follow-up? Prof. Jie Chen: The follow-up and review of neuroendocrine tumor patients need to be closely communicated with doctors, who will formulate different review and follow-up plans according to the size, location, grading and stage of the tumor, and the common follow-up means include serum chromogranin A test, CT, MRI and endoscopy and other imaging examinations. Why does the treatment of neuroendocrine tumors tend to be more and more multidisciplinary? Prof. Jie Chen: Neuroendocrine tumor is a relatively rare disease, which is not well understood by many clinicians, and there are few clear and effective drugs for this disease. Multidisciplinary consultation or multidisciplinary team is particularly important, not only can it improve the understanding of neuroendocrine tumors by clinicians from different disciplines, thus shorten the diagnosis time of neuroendocrine tumor patients, but also can pool patients together and provide more clinical experience for the diagnosis and treatment of neuroendocrine tumors, and also can promote further research on neuroendocrine tumors.